Global CRISPR Gene Editing Market Size Likely to Grow at a CAGR of 13.01% By 2034

Market Size and Growth

As per the CRISPR Gene Editing Market size analysis conducted by the CMI Team, the global CRISPR Gene Editing Market is expected to record a CAGR of 13.01% from 2025 to 2034. In 2025, the market size is projected to reach a valuation of USD 4.10 Billion. By 2034, the valuation is anticipated to reach USD 12.6 Billion.

Overview

As per the industry experts at CMI, Major players in the CRISPR gene editing segment such as CRISPR Therapeutics AG, Agilent Technologies Inc., Thermo Fisher Scientific Inc., and GeneCopoeia Inc., are enhancing precision gene editing via scalable platforms and solutions from synthetic biology. With the automation and genomic cloud computing these companies intend to enhance CRISPR’s precision and efficacy, they will utilize AI-generated guide RNAs.

Other active ventures focus on plant and agricultural biopharmaceuticals, therapeutic biopharmaceuticals, or functional genomics. Collaborations between universities, clinics, and the biotech sector are on the rise, which accelerates innovation and globalization. Compliance with FDA, EMA, ISO, ESG, and CSR requirements strengthens green laboratory sustainability initiatives. These enduring strategic focuses enable still transformative advances in CRISPR.

Key Trends & Drivers

The Rise in Demand for Personalized Medicine: This is the increasing need for treatments based on and tailored to an individual’s genetic composition. This increases efficiency and reduces adverse drug reactions. CRISPR technology aids in this by enabling on-target, specific edits. In March 2025, a CRISPR-based therapy received expanded orphan drug designation from the FDA for treating a rare genetic liver metabolic disorder which marked a regulatory milestone. Furthermore, pharmaceutical manufacturers have several personalized CRISPR clinical programs in progress for sickle cell and retinal diseases. These initiatives highlight the increasing momentum and investment behind tailored patient-specific, gene-editing therapies. As trials expand, the clinical availability of tailored CRISPR therapies approaches reality.

Growth in Agricultural Biotechnology: This concerns the application of CRISPR technology for modification of essential traits in crops like yield, climate resilience and pest resistance to solve food crises around the world. There is relaxed concern with GMO crops as emerging markets are granting less red tape than traditional GMOs to genome edited crops. In late 2024, a multinational agri-biotech consortium conducted successful pilot trials of drought resistant CRISPR maize in sub-saharan Africa. Since then, major seed companies have formed alliances aimed at bringing these next generation crops to market. The surge in the funding of agricultural startups specializing in gene editing technologies reached nearly double the amount received throughout 2024 in the first quarter of 2025. This strongly substantiates the impact and promise of CRISPR on sustainable agriculture.

The Integration of Synthetic Biology: The rise of synthetic biology is a relatively more recent phenomenon within the life sciences. Synthetic biology is the infusion of CRISPR genetic modification into frameworks designated for creating biomaterials, therapeutics, and diagnostics. It promotes creativity by programming biological functions into living organisms. In January 2025, one of the leaders in the industry launched a fully automated CRISPR workstation that designs host organisms for enzyme production. In the same quarter, CRISPR editing kits meant for easier construction of sophisticated metabolic pathways were issued. These tools which permit rapid prototyping and bioproduction, are alleviating constraints in biomanufacturing. The remarkable progress made in synthetic biology is motivating the greater adoption of CRISPR technologies by the industrial and academic sectors.

Report Scope

SWOT Analysis

• Strengths: The applicability of CRISPR technology spans over various domains, from healthcare and agriculture to diagnostics, making it easier to adopt and innovate. Unlike traditional gene editing methodologies, it is much more cost efficient, precise, and effective. Further, it undergoes fewer regulatory roadblocks. Strong competitors, coupled with increased research and development spending, and greater regulatory acceptance for clinical trial approvals also serve to propel the industry. Lastly, the core principles of the technology’s design fosters worldwide ingenuity, industrial adoption, and innovation.

• Weaknesses: Concerns from other sectors such as off target effects and ineffective delivery mechanisms pose significant ethical barriers that conflict with the acceptance of CRISPR technology. Furthermore, lack of global uniform regulations creates disputes of ownership which stifles the key players in the industry. From a public standpoint, these issues damage perception of trust and the ability to scale commercially. There are also broader societal barriers, including the overly complex therapeutic development process and high reliability costs that work counter to public adoption.

• Opportunities: Increased interactions between government and private organizations coupled with the advances in synthetic biology create purpose built medicine and fuel emerging markets. Focused agricultural innovations also enable wide scale adoption in developing nations. With innovations like prime editing and base editing, emerging technologies bring vast commercial prospects. Moreover, automation alongside AI powered guide RNA creates the opportunity for high precision design.

• Threats: Unresolved controversies, including regulatory uncertainty, ethical concerns (particularly relating to germline editing), and biosafety issues, remain looming threats. Market share might be affected by competition from TALEN and ZFN as other alternative technologies for genome editing. Clinical progress may be hampered by legal restrictions or public backlash. In addition, latent cybersecurity risks in digital genomics and the misuse of data continue to be troubling matters.

 List of the prominent players in the CRISPR Gene Editing Market:

• CRISPR Therapeutics AG
• Agilent Technologies Inc.
• Thermo Fisher Scientific Inc.
• GeneCopoeia Inc.
• Synthego Corporation
• System Biosciences LLC
• ToolGen Inc.
• Rockland Immunochemicals Inc.
• Horizon Discovery Group PLC
• Abcam Inc.
• Applied StemCell Inc.
• Cellecta Inc
• Others

The CRISPR Gene Editing Market is segmented as follows:

By Product

• Kits and Reagents
• Services

By Gene Editing Modality

• Ex-Vivo Editing
• In-Vivo Editing

By Technology

• CRISPR/Cas9 Technology
• CRISPR/Cas12 Technology
• Prime Editing
• Epigenetic Editing
• Others

By Application

• Therapeutic Applications
• Agriculture and Livestock
• Industrial Biotechnology

By End User

• Biotechnology and Pharmaceutical Companies
• Agricultural and Livestock Industry
• Hospitals and Clinics
• Others

Regional Coverage:

North America

• U.S.
• Canada
• Mexico
• Rest of North America

Europe

• Germany
• France
• U.K.
• Russia
• Italy
• Spain
• Netherlands
• Rest of Europe

Asia Pacific

• China
• Japan
• India
• New Zealand
• Australia
• South Korea
• Taiwan
• Rest of Asia Pacific

The Middle East & Africa

• Saudi Arabia
• UAE
• Egypt
• Kuwait
• South Africa
• Rest of the Middle East & Africa

Latin America

• Brazil
• Argentina
• Rest of Latin America